Skip to main content

Table 2 Primary outcome analysis

From: Beta-hydroxy beta-methylbutyrate/arginine/glutamine (HMB/Arg/Gln) supplementation to improve the management of cachexia in patients with advanced lung cancer: an open-label, multicentre, randomised, controlled phase II trial (NOURISH)

  HMB/Arg/Gln
n = 19 N (%)
No HMB/Arg/Gln
n = 19 N (%)
Success (alive without a drop of >5% in LBM) 3 (16) 9 (47)
Failure (alive with a drop of >5% in LBM) 3 (16) 3 (16)
Died 4 (21) 1 (5)
Data not-available 9 (47) 6 (32)
Reasons for unavailable data
 Patient withdrawal 6 (67) 1 (17)
 None attendance at week 12 visit 2 (22) 4 (66)
 Measure not taken 1 (11) 1 (17)
  1. HMB/Arg/Gln β-Hydroxy β-Methylbutyrate/Arginine/Glutamine LBM Lean body mass